CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-16 | HERSHBERG ROBERT Director | Grant or award | +12,612 | 38,619 | ||
| 2023-06-16 | HERSHBERG ROBERT Director | Grant or award · Stock Option (Right to Buy) | +25,224 | 25,224 | ||
| 2023-06-16 | Burrell Terry-Ann Director | Grant or award | +12,612 | 171,847 | ||
| 2023-06-16 | Burrell Terry-Ann Director | Grant or award · Stock Option (Right to Buy) | +25,224 | 25,224 | ||
| 2023-06-16 | CHAVEZ R. MARTIN Director | Grant or award | +12,612 | 51,017 | ||
| 2023-06-16 | CHAVEZ R. MARTIN Director | Grant or award · Stock Option (Right to Buy) | +25,224 | 25,224 | ||
| 2023-06-16 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +30,000 | $2.22 | $67K | 173,954 |
| 2023-06-16 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −30,000 | $9.41 | $282K | 143,954 |
| 2023-06-16 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 569,469 | ||
| 2023-06-15 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +30,000 | $2.22 | $67K | 173,954 |
| 2023-06-15 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −30,000 | $9.67 | $290K | 143,954 |
| 2023-06-15 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 599,469 | ||
| 2023-06-15 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 926,378 | ||
| 2023-06-15 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 916,378 | ||
| 2023-06-15 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,541,496 | ||
| 2023-06-14 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 842,913 |
| 2023-06-14 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $10.07 | $252K | 817,913 |
| 2023-06-14 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 745,313 | ||
| 2023-06-13 | Borgeson Blake Director | Sale | −15,485 | $9.98 | $155K | 7,525,262 |
| 2023-06-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 830,413 |
Page 38 of 41 · 805 trades